Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 12182870)

1.

The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.

Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Elliott RL, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ, Whittaker CM.

Bioorg Med Chem Lett. 2002 Sep 16;12(18):2603-6.

PMID:
12182870
2.

N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2.

Boyd HF, Fell SC, Flynn ST, Hickey DM, Ife RJ, Leach CA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Porter RA, Rawlings DA, Smith SA, Stansfield IG, Tew DG, Theobald CJ, Whittaker CM.

Bioorg Med Chem Lett. 2000 Nov 20;10(22):2557-61.

PMID:
11086729
3.

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1067-70.

PMID:
12643913
4.

The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2.

Boyd HF, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Pinto IL, Smith SA, Stansfield IG, Theobald CJ, Whittaker CM.

Bioorg Med Chem Lett. 2001 Mar 12;11(5):701-4.

PMID:
11266173
5.

Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones.

Boyd HF, Fell SC, Hickey DM, Ife RJ, Leach CA, Macphee CH, Milliner KJ, Pinto IL, Rawlings DA, Smith SA, Stansfield IG, Stanway SJ, Theobald CJ, Whittaker CM.

Bioorg Med Chem Lett. 2002 Jan 7;12(1):51-5.

PMID:
11738571
6.

1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A(2).

Bloomer JC, Boyd HF, Hickey DM, Ife RJ, Leach CA, Macphee CH, Milliner KJ, Pinto IL, Rawlings DA, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ, Whittaker CM.

Bioorg Med Chem Lett. 2001 Jul 23;11(14):1925-9.

PMID:
11459662
7.

2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2.

Boyd HF, Flynn ST, Hickey DM, Ife RJ, Jones M, Leach CA, Macphee CH, Milliner KJ, Rawlings DA, Slingsby BP, Smith SA, Stansfield IG, Tew DG, Theobald CJ.

Bioorg Med Chem Lett. 2000 Feb 21;10(4):395-8.

PMID:
10714508
8.

SB-480848. GlaxoSmithKline.

Rotella DP.

Curr Opin Investig Drugs. 2004 Mar;5(3):348-51. Review.

PMID:
15083604
10.

Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy.

Leach CA, Hickey DM, Ife RJ, Macphee CH, Smith SA, Tew DG.

Farmaco. 2001 Jan-Feb;56(1-2):45-50.

PMID:
11347966
11.
12.

Design and synthesis of new orally active inhibitors of human neutrophil elastase.

Ohmoto K, Okuma M, Yamamoto T, Kijima H, Sekioka T, Kitagawa K, Yamamoto S, Tanaka K, Kawabata K, Sakata A, Imawaka H, Nakai H, Toda M.

Bioorg Med Chem. 2001 May;9(5):1307-23.

PMID:
11377188
13.

SB-253514 and analogues; novel inhibitors of lipoprotein-associated phospholipase A2 produced by Pseudomonas fluorescens DSM 11579. I. Fermentation of producing strain, isolation and biological activity.

Thirkettle J, Alvarez E, Boyd H, Brown M, Diez E, Hueso J, Elson S, Fulston M, Gershater C, Morata ML, Perez P, Ready S, Sanchez-Puelles JM, Sheridan R, Stefanska A, Warr S.

J Antibiot (Tokyo). 2000 Jul;53(7):664-9.

14.

Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase.

Ohmoto K, Yamamoto T, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M, Cheronis JC, Spruce LW, Gyorkos A, Wieczorek M.

J Med Chem. 2000 Dec 28;43(26):4927-9. No abstract available.

PMID:
11150162
15.

Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.

Shultz MD, Cheung AK, Kirby CA, Firestone B, Fan J, Chen CH, Chen Z, Chin DN, Dipietro L, Fazal A, Feng Y, Fortin PD, Gould T, Lagu B, Lei H, Lenoir F, Majumdar D, Ochala E, Palermo MG, Pham L, Pu M, Smith T, Stams T, Tomlinson RC, Touré BB, Visser M, Wang RM, Waters NJ, Shao W.

J Med Chem. 2013 Aug 22;56(16):6495-511. doi: 10.1021/jm400807n. Epub 2013 Aug 13.

PMID:
23844574
16.

Inhibition of secretory phospholipase A2. 2-Synthesis and structure-activity relationship studies of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one (PMS1062) derivatives specific for group II enzyme.

Dong CZ, Ahamada-Himidi A, Plocki S, Aoun D, Touaibia M, Meddad-Bel Habich N, Huet J, Redeuilh C, Ombetta JE, Godfroid JJ, Massicot F, Heymans F.

Bioorg Med Chem. 2005 Mar 15;13(6):1989-2007.

PMID:
15727853
17.

(E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors.

Jeong TS, Kim MJ, Yu H, Kim KS, Choi JK, Kim SS, Lee WS.

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1525-7.

PMID:
15713421
19.

D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity.

Hansford KA, Reid RC, Clark CI, Tyndall JD, Whitehouse MW, Guthrie T, McGeary RP, Schafer K, Martin JL, Fairlie DP.

Chembiochem. 2003 Mar 3;4(2-3):181-5.

PMID:
12616631
20.

Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.

Hille UE, Hu Q, Vock C, Negri M, Bartels M, Müller-Vieira U, Lauterbach T, Hartmann RW.

Eur J Med Chem. 2009 Jul;44(7):2765-75. doi: 10.1016/j.ejmech.2009.01.002. Epub 2009 Jan 19.

PMID:
19211174
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk